Product Images Pemetrexed

This is a drug called Pemetrexed for Intravenous use only. Each vial contains 100 mg of Pemetrexed disodium and other components to adjust pH. It is a cytotoxic agent and unused contents should be discarded. It is a single-dose drug and is manufactured by Eugia Pharma Specialities Ltd. Storage instructions can be found in the package insert. No other information is available due to the limited text provided.*

This is a product description for Pemetrexed Injection, USP, a cytotoxic agent that is administered intravenously. Each vial contains pemetroxed sodum equivalent to 100 mg of pemeliaxed. Users are advised to refer to the package insert for dosages. The product should be reconstituted by adding 42 Lol of 3% Sodium Chloride injection. The unused portion should be discarded, and administration must be carried out within 24 hours of reconstitution. The v-topper is not made with natural fiber. The product is manufactured by Eugla Pharma Specialtios Lintod and is exclusively distributed by BluePoint Laboratories.*

NDC 68001-536-41 is a prescription-only drug that contains pemetrexed disodium. Each vial of the drug manufactured by Eugia Pharma Specialities Limited contains 10500 mg of pemetrexed and 500 mg of mannitol. It is prescribed for intravenous use only and is a cytotoxic agent that should be stored in controlled room temperature between 15 to 30°C (59 to 86°F). Discard any unused portion of the drug and refer to the package insert for instructions on storage of reconstituted single-dose infusion solutions. However, the last line seems to contain non-English characters so it is excluded.*

This is a description of a drug called Pemetrexed, used for injection, and should only be administered intravenously. It is a cytotoxic agent and comes in a single-dose vial. The vial contains pemetrexed dsodum equivalent to 500mg pemetrexed. The medication needs to be reconstituted by using diluted Sosum Chlode Infection one to make a solution containing 25mgimL pemetexed. This solution must be further diluted before use. The recommended usage and dosage will be found in the package insert. The drug should be stored at 25°C (77°F); excursions permitted 0 15 1030°, unopened must be refrigerated at 2°C-8°C (@ 1046%7). The vial should be discarded after the provision of the dose. The drug is manufactured by Eugia Pharma Specialties Limited in MedchalMakajgh District, India. The text also includes a specific identifier number and barcode.*

This is a description of a prescription drug called Pemetrexed manufactured by Eugia Pharma Specialities Limited. Each vial of the drug contains disodium equivalent to 1,000 mg and mannitol. Pemetrexed is for intravenous use only and is a cytotoxic agent. It should be stored at 25°C with permitted excursions to 15-30°C. Unused portions should be discarded, and dosage should be reconstituted and infused as per package instructions. The text also includes a code "TS/DRUGS/24/2015" and a revision date of May 2022.*

This is a pharmaceutical product labeled Pemetrexed for Injection. It comes in a single-dose vial containing 1,000mg of the drug, and it is a cytotoxic agent to be used intravenously. The powder should be stored at 25°C, and the reconstituted solution must be refrigerated before use. The contents of the package insert should be reviewed for usual dosage, and the drug should be administered within 24 hours of reconstitution. The vialstopper of this product is not made of natural rubber latex. The manufacturer is Eugla Pharma Specialities Limited in India, and the product is intended for use by BlusPoint Laboratories.*

This appears to be a graph comparing the survival probability and time in months for two different types of treatments named "Pemetrexed + Csplatin (PC)" and "Gemcitabine + Cisplatin (GC)" for patients. The y-axis represents the survival probability from 0% to 100% and the x-axis depicts the survival time in months. There are also two lines representing the survival probability of each treatment. The PC treatment line is labeled with blue and the GC treatment line is labeled with orange. The graph also includes a table displaying the "Patients at Risk" for both treatment types at each given time point.*

This text is describing a comparison between the survival probability of two treatments: Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The data shows the number of patients at risk and the survival time in months, indicating that more patients survived longer with GC treatment.*

This appears to be a table showing the Survival Probability of patients who were either given pemetrexed or placebo. The table also provides the number of patients at risk and their survival time in months.*

This appears to be a chart or a table comparing the survival times in months of patients who were administered Pemetrexed and Placebo. There are columns representing months and rows showing the number of patients alive at that specific time point. It appears that patients who received Pemetrexed lived longer than those who did not.*

This is a survival probability chart for patients that have received Pemetrexed and Cisplatin. It shows the number of patients at risk and their probability of surviving over a period of time, which is measured in months. The chart indicates the survival times of patients who have received the treatment of Pemetrexed and Cisplatin. The chart provides data points of corresponding survival rates for patients receiving the treatment.*